

**510(k) Summary**  
**ArthroCare® Corporation**  
TURBINATOR™ WAND

**JUL 02 2013**

**General Information**

Submitter Name: ArthroCare Corporation  
Address: 7000 West William Cannon Drive  
Austin, TX 78735  
Contact Person: Ashley J Dawson, PhD  
Manager, Regulatory Affairs  
Date Prepared: August 21, 2012

**Device System Names/Components**

Proprietary: ArthroCare® Turbinator™ Wand  
Common: Turbinator Wand  
Classification: Class II  
Product Code: GEI  
CFR Section: 21 CFR 878.4400

**Predicate Device**

ReFlex Ultra 45 included in:

ArthroCare® ENT Plasma Wands™ K070374 (April 25, 2007)

**Description**

The ArthroCare Turbinator Wand is a bipolar, single use, electrosurgical device designed for use with the ArthroCare Coblator II System Controller for specific turbinate indications in otorhinolaryngology (ENT) procedures.

**Intended Use/Indications For Use**

The Turbinator Wand is indicated for ablation, resection, and coagulation of soft tissue and hemostasis of blood vessels in otorhinolaryngology (ENT) surgery involving nasal airway obstruction by reduction of hypertrophic nasal turbinates and submucosal tissue shrinkage. The wand is designed to be used exclusively with the ArthroCare Coblator II (CII) controller and ArthroCare Irrigation pump. Other controllers/pumps must not be used.

### **Performance Testing - Bench**

Bench testing was performed to evaluate the performance of the Turbinator Wand compared to the predicate ReFlex Ultra 45. The test results demonstrate that the Turbinator Wand meets all design and performance specifications.

### **Performance Testing – Animal**

A Pre-Clinical study was also conducted to evaluate the tissue effects using the Turbinator Wand compared to the ReFlex Ultra 45. Based on the test results, the proposed device is substantially equivalent to the predicate device.

### **Performance Testing – Clinical**

No clinical data are included in this submission.

### **Summary**

All testing demonstrates that the ArthroCare Turbinator Wand performs as intended when used in accordance with its labeling. The ArthroCare Turbinator Wand has similar technological characteristics (i.e., design, material, chemical composition, energy source) as compared to the predicate ArthroCare ReFlex Ultra 45 Wand. The Turbinator Wand incorporates conductive media delivery and suction as well as higher setpoints for Coblation plasma formation. The modified ArthroCare Turbinator Wand, as described in this submission, is substantially equivalent to the predicate ArthroCare ReFlex Ultra 45 Wand. The proposed modifications in Indications for Use, performance specifications, materials, and labeling are not substantial changes or modifications, and do not raise new questions of safety or effectiveness.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G609  
Silver Spring, MD 20993-0002

ArthroCare Corporation  
C/O Mitchell Dhority  
Vice President, Clinical and Regulatory Affairs  
7000 West William Cannon Drive  
Austin, TX 78735

July 2, 2013

Re: K122652

Trade/Device Name: ArthroCare<sup>®</sup> Turbinator<sup>™</sup> Wand  
Regulation Number: 21 CFR 878.4400  
Regulation Name: Electrosurgical cutting and coagulation device and accessories  
Regulatory Class: Class II  
Product Code: GEI  
Dated: June 27, 2013  
Received: June 28, 2013

Dear Mr. Dhority:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).

You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

Page 2 – Mr. Mitchell Dhority

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**Mark N. Melkerson -S**

Mark N. Melkerson  
Acting Director  
Division of Surgical Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

